VIDEO: Results of IMbrave050 trial ‘potentially practice-changing’
In this video, Daneng Li, MD, a medical oncologist at City of Hope, discussed results from the Phase 3 IMbrave050 trial presented at American Association for Cancer Research Annual Meeting.
Li examined the study, which found increased recurrence-free survival of patients with hepatocellular carcinoma treated with adjuvant therapy with atezolizumab (Tecentriq, Genentech) and bevacizumab (Avastin, Genentech) among a sample of high-risk patients selected based on tumor size, number and differentiation.
“We have never before in the setting of HCC — which is a very aggressive cancer — been able to have a postoperative or post-ablation treatment to decrease the risk [for] recurrence and potentially cure someone of their HCC,” Li said. “If this is approved, this is potentially practice changing.”
Collapse
Read more about